An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
Top results in this bookTable of Contents
Ibrutinib (Imbruvica): CADTH Reimbursement Review: Therapeutic area: Waldenström macroglobulinemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Apr.
Zanubrutinib (Brukinsa): CADTH Reimbursement Review: Therapeutic area: Waldenström macroglobulinemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.
Evidence reviews for bleeding disorders: Intrapartum care for women with existing medical conditions or obstetric complications and their babies: Evidence review F.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2019 Mar. (NICE Guideline, No. 121.)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Zanubrutinib (Brukinsa): CADTH Reimbursement Recommendation: Indication: For the treatment of patients with Waldenström macroglobulinemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Dec.
Zanubrutinib (Brukinsa): CADTH Reimbursement Review: Therapeutic area: Chronic lymphocytic leukemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov.
Holland-Frei Cancer Medicine. 6th edition.
Kufe DW, Pollock RE, Weichselbaum RR, et al., editors.
Hamilton (ON): BC Decker; 2003.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].
Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
Zanubrutinib (Brukinsa): CADTH Reimbursement Review: Therapeutic area: Mantle cell lymphoma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep.
Evidence review for information for women with existing medical conditions: Intrapartum care for women with existing medical conditions or obstetric complications and their babies: Evidence review A.
Evidence review for antenatal care planning involving a multidisciplinary team for women with existing medical conditions: Intrapartum care for women with existing medical conditions or obstetric complications and their babies: Evidence review B.
Comparative Oncology.
Baba AI, Câtoi C.
Bucharest (RO): The Publishing House of the Romanian Academy; 2007.
Axicabtagene ciloleucel (Yescarta): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory grade 1, 2, or 3a follicular lymphoma after 2 or more lines of systemic therapy [Internet].
Tisagenlecleucel (Kymriah): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory grade 1, 2, or 3a follicular lymphoma after 2 or more lines of systemic therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Sep.
World Cancer Report: Cancer research for cancer prevention.
Wild CP, Weiderpass E, Stewart BW, editors.
Lyon (FR): International Agency for Research on Cancer; 2020.
Teclistamab (Tecvayli): Therapeutic area: Relapsed or refractory multiple myeloma: CADTH Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Sep.
Multi-cancer early detection tests for general population screening: a systematic literature review.
Wade R, Nevitt S, Liu Y, et al.
Southampton (UK): National Institute for Health and Care Research; 2025 Jan. (Health Technology Assessment, No. 29.02.)
Zanubrutinib (Brukinsa): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Aug.
Selinexor (Xpovio): CADTH Reimbursement Review: Therapeutic area: Multiple myeloma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on